- Preliminary data from the first patient trial of the bispecific antibody FS222 indicate a manageable toxicity profile and promising antitumor activity.
- The drug has been tested in patients with various types of advanced solid tumors such as lung cancer, ovarian cancer, or melanoma, who had been treated previously. The overall response rate was 17%. Notable results were observed in patients with metastatic cutaneous melanoma who had not responded to immunotherapy. In these patients, the response rate was 47,4% and the disease was controlled in 68,4 % of the patients.
- Dr Elena Garralda, medical oncologist and director of the Molecular Cancer Therapy Research Unit UITM-CaixaResearch at VHIO, presents this data today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from 31 May to 4 June in Chicago.
- The Molecular Cancer Therapy Research Unit UITM-CaixaResearch at VHIO is supported by the “la Caixa” Foundation.
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy with anti-PD1 immune checkpoint inhibitors.
Promising antitumor activity data, especially in melanoma patients
The ongoing trial has already included 104 patients with various types of tumors who had received between one and seven previous courses of treatment. Preliminary results from this phase 1 trial indicate partial or complete objective response rates in patients with melanoma, non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, liposarcoma, and colon cancer.
The overall response rate for all tumor types was 17%. “However,” adds Dr Elena Garralda, director of the Molecular Cancer Therapy Research Unit UITM-CaixaResearch, who led this study, “the results stand out in patients with advanced cutaneous melanoma who had not responded to immunotherapy with immune checkpoint inhibitors”. In these patients, the overall response rate was 47,4%, and the disease was controlled in 68,4 % of the patients.
“Although these are very preliminary results, they are indeed very promising, especially in patients with melanoma who do not respond to conventional immunotherapy,” comments Elena Garralda.
The adverse effects associated with the treatment show an acceptable and manageable safety profile for the drug. Regarding pharmacology, modulation and increase of tumor T cells were observed in biopsies of treated patients, confirming the activation of the immune response against the tumor.
Innovative design to reactivate the immune response against the tumor
“Although the advent of immunotherapy has been a revolution in the landscape of cancer treatment, to this day, most patients receiving immune checkpoint inhibitors do not respond to the treatment or relapse. Hence, the need to continue researching to find new immunotherapy strategies that offer greater benefits to a larger number of patients,” explains Dr Elena Garralda.
FS222 is an innovative next-generation bispecific antibody. Its tetravalent structure allows it to inhibit the PD-L1 immune checkpoint on one side and presents an agonist or enhancer of the immune response on the other. This enables it to very potently and selectively activate the patient’s immune system against tumor cells.
“Next steps include a better optimization of dose selection and further evaluation of the efficacy profile of FS222 in patients with melanoma and other tumor types to confirm activity in a larger number of patients,” concludes Dr Garralda, who presented these preliminary data from the first human trial of this innovative antibody today at the 2024 ASCO Annual Meeting, held in Chicago from 31 May to 4 June.
References
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.
Elena Garralda, Arjun Oberoi, Guillermo de Velasco, Iván Victoria, David Pesantez, Inaki Eguren, Santamaría, Victor Moreno, Valentina Boni, Andres Cervantes, Valentina Gambardella, Tudor-Eliade, Ciuleanu, Milana Bergamino Sirvén, Delvys Rodriguez-Abreu, Guzman Alonso, Laurentia Minea Gales, Daniel Jones, Abhay Patki, Ozlem Ataman, Ignacio Melero Bermejo.
2024 ASCO Annual Meeting
Oral Abstract Session: Developmental Therapeutics—Immunotherapy
Primary Track: Developmental Therapeutics—Immunotherapy
Monday June 3rd – 18:30 CEST
Speaker: Elena Garralda, MD, MSc, Vall d’Hebron University Hospital (HUVH) and Vall d’Hebron Institute of Oncology (VHIO)
Chairs: Tian Zhang, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern; Abdul Rafeh Naqash, University of Oklahoma Health Sciences Center, Stephenson Cancer Center
About VHIO
The Vall d’Hebron Institute of Oncology (VHIO), established in 2006 and located within the Vall d’Hebron Campus, is a reference comprehensive cancer center for personalized medicine in oncology. Through our purely translational and multidisciplinary research model, we aim to improve the prevention, early diagnosis and treatment of cancer by transforming the latest scientific discoveries made in the laboratory into early phase clinical trials for the development of more effective therapies to improve the quality of life and survival of cancer patients.
VHIO forms part of the CERCA – Research Centres of Catalonia system and is accredited as a Severo Ochoa Center of Excellence.
Research at VHIO would not be possible without the support received from our patrons – Generalitat de Catalunya, Fundació Privada CELLEX, “La Caixa” Foundation, Fundación FERO, and the Fundación BBVA, the public funding it receives as well as the generous support from institutional supporters, private institutions, companies, associations, societies, and individual donors. Only with such continued support will VHIO continue to advance personalized and targeted therapies against cancer.
